0001127602-21-027697.txt : 20211027 0001127602-21-027697.hdr.sgml : 20211027 20211027162620 ACCESSION NUMBER: 0001127602-21-027697 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211020 FILED AS OF DATE: 20211027 DATE AS OF CHANGE: 20211027 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DeLong Mark Jeffrey CENTRAL INDEX KEY: 0001856078 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 211353318 MAIL ADDRESS: STREET 1: 100 5TH AVENUE, 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2021-10-20 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001856078 DeLong Mark Jeffrey C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Senior Vice President Common Stock 2021-10-20 4 A 0 882 0 A 10372 D This represents a restricted stock unit that vest 50% annually over two years from grant date, subject to continued service. /s/ David Watson, attorney-in-fact for Mark Delong 2021-10-27